Please login to the form below

Not currently logged in
Email:
Password:

UK government ‘concerned’ over Elliott Management’s plans for GSK

'Activist' hedge fund Elliott Management has built up a sizeable stake in the British drugmaker

The UK government has concerns over activist investor Elliott Management’s plans for GlaxoSmithKline (GSK) after the hedge fund acquired a ‘significant’ stake in the British drugmaker last month.

According to The Times, Britain’s Secretary of State for Business, Energy and Industrial Strategy is believed to have asked government officials to back GSK’s chief executive officer Emma Walmsley – in particular her ongoing restructuring of the company.

There is speculation over what exactly Elliott Management’s plans for the company could entail – with potential scenarios being the sale of GSK or its pharmaceuticals or vaccines divisions.

Walmsley has come under increasing pressure to improve GSK’s performance ahead of a planned split of the company’s consumer health and pharma divisions, which is 'well underway'.

The split, which was initially announced in 2018, will result in GSK being separated into two companies – one focusing on speciality pharma and the other focusing on consumer healthcare.

Following the planned completion of the separation, due in mid-2022, GSK will remain solely focused on pharmaceuticals and vaccine products.

In addition, the British drugmaker has faced a number of setbacks recently, in particular relating to a delay of its Sanofi-partnered COVID-19 vaccine, although GSK recently revealed positive data for the jab, along with data on another plant-derived vaccine in development with Canadian biotech Medicago.

Further tension emerged last month after it was reported that activist hedge fund Elliott Management had built up a sizeable stake in the British drugmaker.

Elliott Management is known to be an ‘aggressive activist’ investor – in the pharma industry, the hedge fund petitioned for the sale of Alexion Pharmaceuticals ahead of its subsequent acquisition by AstraZeneca in December 2020.

Last week, however, major shareholders threw their support behind Walmsley and GSK’s executive team, including BlackRock, the drugmaker’s largest investor as well as Royal London and Dodge & Cox.

All three shareholders have reportedly been in contact with Jonathan Symonds, chairman of GSK, to offer their support in a potential clash with Elliott Management, according to The Mail.

Article by
Lucy Parsons

25th May 2021

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...